Microstructural Imaging of Neurodegenerative Changes

[1]  M. Viitanen,et al.  PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment , 2007, Neurology.

[2]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[3]  J. Trojanowski,et al.  Isomerization of (Z,Z) to (E,E)1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in strong base: probes for amyloid plaques in the brain. , 2001, Journal of medicinal chemistry.

[4]  P. Lantos,et al.  The Neuropathology of Alzheimer’s Disease , 1994 .

[5]  D. Dickson,et al.  Alzheimer neurofibrillary lesions: Molecular nature and potential roles of different components , 1995, Neurobiology of Aging.

[6]  F. Mottaghy,et al.  Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of β-amyloid plaques , 2007, Nuklearmedizin.

[7]  D. Kuhl,et al.  Neurochemical imaging of dementias. , 2004, Seminars in nuclear medicine.

[8]  J. Bohl,et al.  Stage-dependent and sector-specific neuronal loss in hippocampus during Alzheimer's disease , 2002, Acta Neuropathologica.

[9]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[10]  D. Selkoe,et al.  Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. , 1994, Annual review of cell biology.

[11]  Gina N. LaRossa,et al.  [11C]PIB in a nondemented population , 2006, Neurology.

[12]  J. Troncoso,et al.  Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease , 1994, The Lancet.

[13]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[14]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .

[15]  H. Kung,et al.  Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. , 2006, Journal of medicinal chemistry.

[16]  V. Kepe,et al.  In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer’s brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile , 2003, Neuroscience.

[17]  Nigel J. Cairns,et al.  Neurons, intracellular and extracellular neurofibrillary tangles in subdivisions of the hippocampal cortex in normal ageing and Alzheimer's disease , 1995, Neuroscience Letters.

[18]  H. Kung,et al.  Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. , 2006, Bioorganic & medicinal chemistry letters.

[19]  Gaj Vidmar,et al.  The 2,6‐Disubstituted Naphthalene Derivative FDDNP Labeling Reliably Predicts Congo Red Birefringence of Protein Deposits in Brain Sections of Selected Human Neurodegenerative Diseases , 2006, Brain pathology.

[20]  T. Wisniewski,et al.  Biology of Aβ Amyloid in Alzheimer's Disease , 1997, Neurobiology of Disease.

[21]  Peter T. Lansbury,et al.  A REDUCTIONIST VIEW OF ALZHEIMER'S DISEASE , 1996 .

[22]  D. Salmon,et al.  Cognitive screening and neuropsychological assessment in early Alzheimer's disease. , 2001, Clinics in geriatric medicine.

[23]  H. Kung,et al.  Dimethylamino-fluorenes: ligands for detecting β-amyloid plaques in the brain , 2003 .

[24]  A. Delacourte,et al.  The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease , 1999, Neurology.

[25]  S. DeKosky,et al.  Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.

[26]  K. Iqbal.  Alzheimer's disease : basic mechanisms, diagnosis and therapeutic strategies , 1991 .

[27]  W. Klunk,et al.  X-34, A Fluorescent Derivative of Congo Red: A Novel Histochemical Stain for Alzheimer's Disease Pathology , 2000, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[29]  D. Evans,et al.  Estimated prevalence of Alzheimer's disease in the United States. , 1990, The Milbank quarterly.

[30]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[31]  E. Tangalos,et al.  Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.

[32]  V. Kepe,et al.  Exploring a Mathematical Model for the Kinetics of β-Amyloid Molecular Imaging Probes through a Critical Analysis of Plaque Pathology , 2006, Molecular Imaging and Biology.

[33]  Masahiro Ono,et al.  Radioiodinated Flavones for in Vivo Imaging of β-Amyloid Plaques in the Brain , 2005 .

[34]  D. Mann,et al.  Pyramidal nerve cell loss in Alzheimer's disease. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[35]  G. Small,et al.  Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. , 2003, Molecular Genetics and Metabolism.

[36]  J. Wegiel,et al.  Relationships between Regional Neuronal Loss and Neurofibrillary Changes in the Hippocampal Formation and Duration and Severity of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[37]  Michael V. Green,et al.  PET imaging of brain with the β-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  D. Knopman,et al.  Prevalence, costs, and treatment of Alzheimer's disease and related dementia: a managed care perspective. , 2001, The American journal of managed care.

[39]  J. Morrison,et al.  Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.

[40]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[41]  P. Hof,et al.  Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population , 1994, Acta Neuropathologica.

[42]  T. Miyakawa,et al.  Ultrastructural studies of amyloid fibrils and senile plaques in human brain , 2004, Acta Neuropathologica.

[43]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[44]  M. Staufenbiel,et al.  Styrylbenzoxazole Derivatives for In Vivo Imaging of Amyloid Plaques in the Brain , 2004, The Journal of Neuroscience.

[45]  Alan A. Wilson,et al.  In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[46]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[47]  H. Kung,et al.  F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. , 2005, Journal of medicinal chemistry.

[48]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[49]  H. Braak,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[50]  Sean R. Donohue,et al.  Synthesis and Evaluation of Two 18F-Labeled 6-Iodo-2-(4′-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine Derivatives as Prospective Radioligands for β-Amyloid in Alzheimer’s Disease , 2004 .

[51]  T. Wisniewski,et al.  Disease modifying approaches for Alzheimer's pathology. , 2007, Current pharmaceutical design.

[52]  Bradley T. Hyman,et al.  Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.

[53]  M. Mesulam,et al.  Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. , 2003, Archives of neurology.

[54]  J. Trojanowski,et al.  IBOX(2-(4'-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. , 2001, Nuclear Medicine and Biology.

[55]  J. Barrio,et al.  Molecular-Imaging Probe 2-(1-{6-[(2-Fluoroethyl)(Methyl) Amino]-2-Naphthyl}Ethylidene) Malononitrile Labels Prion Plaques In Vitro , 2003, The Journal of Neuroscience.

[56]  R. Cohen.  The Application of Positron-Emitting Molecular Imaging Tracers in Alzheimer’s Disease , 2007, Molecular Imaging and Biology.

[57]  D. Kirschner,et al.  Structural analysis of Alzheimer's beta(1-40) amyloid: protofilament assembly of tubular fibrils. , 1998, Biophysical journal.

[58]  R. Friedland,et al.  Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease , 1994, Molecular Neurobiology.

[59]  Sung-Cheng Huang,et al.  Serotonin 1A receptors in the living brain of Alzheimer's disease patients. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[60]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[61]  L. Serpell,et al.  Alzheimer's amyloid fibrils: structure and assembly. , 2000, Biochimica et biophysica acta.

[62]  B. Seilheimer,et al.  The toxicity of the Alzheimer's beta-amyloid peptide correlates with a distinct fiber morphology. , 1997, Journal of structural biology.

[63]  Pawel Sikorski,et al.  Molecular basis for amyloid fibril formation and stability. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Kazuhiro Ito,et al.  Aurones serve as probes of β-amyloid plaques in Alzheimer’s disease , 2007 .

[65]  P. Adlard,et al.  The cause of neuronal degeneration in Alzheimer's disease , 2000, Progress in Neurobiology.

[66]  J. Morrison,et al.  Life and death of neurons in the aging brain. , 1997, Science.

[67]  Sung-Cheng Huang,et al.  2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[68]  Alan A. Wilson,et al.  11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. , 2003, Nuclear medicine and biology.

[69]  B. Winblad,et al.  Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. , 1999, Archives of neurology.

[70]  Brian J Cummings,et al.  β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease , 1996, Neurobiology of Aging.

[71]  H. Kung,et al.  F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. , 2005, Nuclear medicine and biology.

[72]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[73]  G. Small,et al.  Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease , 2001, The Journal of Neuroscience.

[74]  Kazuhiko Yanai,et al.  2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy)Benzoxazole: A Novel PET Agent for In Vivo Detection of Dense Amyloid Plaques in Alzheimer's Disease Patients , 2007, Journal of Nuclear Medicine.

[75]  D. Teplow,et al.  Structural and kinetic features of amyloid beta-protein fibrillogenesis. , 1998, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[76]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[77]  E. Mandelkow,et al.  Tau in Alzheimer's disease. , 1998, Trends in cell biology.

[78]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[79]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[80]  H. Braak,et al.  Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer? , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[81]  Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Keith A. Johnson,et al.  Neuropathology of Cognitively Normal Elderly , 2003, Journal of neuropathology and experimental neurology.

[83]  N. Okamura,et al.  In vivo labeling of amyloid with BF-108 , 2004, Neuroscience Research.

[84]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[85]  E. Tangalos,et al.  Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.

[86]  J. Vickers,et al.  The morphological phenotype of β-amyloid plaques and associated neuritic changes in Alzheimer’s disease , 2001, Neuroscience.

[87]  M. J. Wade,et al.  Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. , 2001, Archives of neurology.

[88]  M. Umemiya,et al.  A Calcium-Dependent Feedback Mechanism Participates in Shaping Single NMDA Miniature EPSCs , 2001, The Journal of Neuroscience.

[89]  D. Skovronsky,et al.  Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[90]  D. Bennett,et al.  Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment , 2001, Annals of neurology.

[91]  E. Mandelkow,et al.  Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain. , 2004, Biochemistry.

[92]  J. Morris,et al.  Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[93]  P. Hof.  Morphology and Neurochemical Characteristics of the Vulnerable Neurons in Brain Aging and Alzheimer’s Disease , 1997, European Neurology.

[94]  H. Arai,et al.  Quinoline and Benzimidazole Derivatives: Candidate Probes for In Vivo Imaging of Tau Pathology in Alzheimer's Disease , 2005, The Journal of Neuroscience.

[95]  George Perry,et al.  Senile plaque composition and posttranslational modification of amyloid-β peptide and associated proteins , 2002, Peptides.

[96]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[97]  B L Miller,et al.  Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease , 2007, Neurology.

[98]  J. Trojanowski,et al.  IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques , 2002, Brain Research.

[99]  G. Small,et al.  Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization. , 2005, Nuclear medicine and biology.

[100]  A. Levey,et al.  Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging β-amyloid in Alzheimer’s disease , 2006 .

[101]  Satoshi Minoshima,et al.  Imaging Alzheimer's disease: clinical applications. , 2003, Neuroimaging clinics of North America.

[102]  Martin von Bergen,et al.  Tau aggregation is driven by a transition from random coil to beta sheet structure. , 2005, Biochimica et biophysica acta.

[103]  B. Hyman,et al.  Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy‐X04, a Systemically Administered Congo Red Derivative , 2002, Journal of neuropathology and experimental neurology.

[104]  W. Pardridge,et al.  Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. , 2000, Bioconjugate chemistry.

[105]  D. Selkoe,et al.  X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.